Business · 14/05/1999Updated: 10/17/2026 · 1 min read
FDA Proposes Changes to Blood Derivative Regulations to Align with Current Practices
Summary
The Food and Drug Administration (FDA) is proposing to update its regulations for blood derivative products to make them more consistent with current practices, following its 'Blood Initiative' to review and revise its policies and procedures related to blood products.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →